Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Regen BioPharma (RGBP) over the last 12 years, with Q4 2025 value amounting to $6.8 million.

  • Regen BioPharma's Total Current Liabilities rose 1600.58% to $6.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.8 million, marking a year-over-year increase of 1600.58%. This contributed to the annual value of $6.6 million for FY2025, which is 2189.02% up from last year.
  • As of Q4 2025, Regen BioPharma's Total Current Liabilities stood at $6.8 million, which was up 1600.58% from $6.6 million recorded in Q3 2025.
  • In the past 5 years, Regen BioPharma's Total Current Liabilities ranged from a high of $77.4 million in Q1 2022 and a low of $5.2 million during Q1 2024
  • In the last 5 years, Regen BioPharma's Total Current Liabilities had a median value of $5.9 million in 2024 and averaged $10.6 million.
  • As far as peak fluctuations go, Regen BioPharma's Total Current Liabilities surged by 137426.74% in 2022, and later crashed by 9310.37% in 2023.
  • Quarter analysis of 5 years shows Regen BioPharma's Total Current Liabilities stood at $10.5 million in 2021, then tumbled by 49.49% to $5.3 million in 2022, then fell by 0.98% to $5.2 million in 2023, then grew by 11.88% to $5.9 million in 2024, then increased by 16.01% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q4 2025, $6.6 million for Q3 2025, and $6.0 million during Q2 2025.